Treatment
CAR-T cells clinical trials
We’re tracking 534 recruiting studies that include CAR-T cells, each written for real people, not researchers, below.
Recruiting studies
- NCT05436496RecruitingPhase 1/Phase 2
CAR-T treatment for certain CD19 or CD70 blood cancers
This early-phase trial tests a customized immune cell therapy (CAR-T) that targets cancer cells with CD19 or CD70 markers on their surface. It may help your body fight the cancer by directing new immune cells to recognize and attack those cells.
Shenzhen, GuangdongAges 6 months–75 years - NCT05436509RecruitingPhase 1/Phase 2
CD19/79b CAR-T therapy for certain B-cell cancers
This early-phase study tests a one-time engineered immune-cell treatment (CAR-T) made to recognize CD19 and CD79b on certain cancer cells. It may help people with specific B-cell cancers, but you must meet several health and infection-safety requirements to join.
Shenzhen, GuangdongAges 6 months–75 years - NCT06084286RecruitingPhase 1
CAR-T therapy targeting CLDN18.2 and PD-L1 for advanced solid tumors
This trial tests a new type of cell therapy (CAR-T) that targets two proteins, CLDN18.2 and PD-L1, found on some cancer cells. It is for people with advanced solid tumors like stomach, esophageal, or pancreatic cancer that have stopped responding to standard treatments.
Chengdu, SichuanAges 18–75 - NCT07470073RecruitingEarly Phase 1
Universal CAR-T cell therapy for B-cell leukemia (ages 12-75)
This trial tests a new type of CAR-T cell therapy (called universal CAR-T) that targets CD19 and CD20 markers on cancer cells. It is for people aged 12 to 75 with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back after treatment.
Wuhan, HubeiAges 12–75 - NCT06612645RecruitingPhase 1
CAR T cell therapy for children with solid tumors that returned
This trial tests a new type of immune therapy called CAR T cells designed to find and attack a protein called B7-H3 on solid tumor cells. It's for children and young adults whose cancer came back or didn't respond to standard treatment.
Bangkok, PathumwanAges 1–25 - NCT06333275Recruiting
Boosting immunity after CAR-T therapy
This trial checks if giving vaccines after CAR-T cell therapy can help your immune system fight off preventable diseases. It is for adults with certain blood cancers who are about to get CAR-T treatment.
BernAges 18 years+ - NCT07247396RecruitingPhase 1
CEA CAR-T therapy after surgery for colorectal cancer spread
This trial tests a special immune cell therapy (CAR-T) that targets a protein called CEA on cancer cells. It is for people with colorectal cancer that has spread to the lining of the belly (peritoneum) and who have already had surgery to remove as much of the spread as possible.
Hangzhou, ZhejiangAges 18–75 - NCT04684459RecruitingEarly Phase 1
CAR-T therapy for tumors with HER2 and PD-L1 markers
This early-phase trial tests CAR-T cells designed to attack tumors that have high HER2 and PD-L1. It may help people with certain solid cancers that have not responded well to standard treatment.
Chengdu, SichuanAges 18–75 - NCT07003295RecruitingPhase 2
Glofitamab for mantle cell lymphoma that returned after CAR-T
This trial tests a new drug, glofitamab, for mantle cell lymphoma that came back or didn’t respond after CAR-T cell therapy. It aims to see if glofitamab can shrink or control the lymphoma.
Duarte, CaliforniaAges 18 years+ - NCT05979363RecruitingPhase 2
CAR-T cell therapy for plasma cell leukemia patients
This trial tests a combination of drugs (bortezomib, lenalidomide, and dexamethasone) followed by a special cell therapy called CAR-T that targets a protein (BCMA) on cancer cells. It is for people with a rare and aggressive blood cancer called primary plasma cell leukemia who are not able to have a stem cell transplant.
TianjinAges 18–75 - NCT05995041RecruitingPhase 1
Universal CAR-T cells for acute myeloid leukemia
This trial tests a type of immunotherapy called CAR-T cells that are made to target leukemia cells. The cells are designed to attack AML by recognizing several proteins on the cancer cells, and may be an option for patients who have not responded well to other treatments.
Shenzhen, GuangdongAges 6 months–75 years - NCT05998928RecruitingPhase 2
BCMA-GPRC5D CAR-T for relapsed or refractory multiple myeloma
This trial tests a new cell therapy (CAR-T) that targets two proteins on myeloma cells for patients whose cancer has returned or not responded after at least three prior treatments. It aims to see if this therapy is safe and effective.
Wuhan, HubeiAges 18–75 - NCT06006390RecruitingPhase 1/Phase 2
CAR-T therapy for CEA-positive advanced solid tumors
This trial tests a new treatment called CAR-T cells that are designed to find and attack cancer cells carrying a protein called CEA. It is for people with advanced colorectal, esophageal, stomach, or pancreatic cancer who have already tried other treatments.
Taiyuan, ShanxiAges 18 years+ - NCT06010862RecruitingPhase 1
CAR-T therapy for CEA-positive advanced cancers
This trial tests a new type of immune cell therapy (called CAR-T) that targets a protein called CEA on cancer cells. It is for people with advanced colorectal, esophageal, stomach, or pancreatic cancer who have already tried standard treatments without success.
Nanchang, JiangxiAges 18 years+ - NCT06056921RecruitingPhase 1
CAR T-cell therapy for hard-to-treat autoimmune diseases
This trial tests a new treatment using your own immune cells (CAR T-cells) targeting a protein called CD19 to control severe autoimmune diseases like lupus, Sjogren's, scleroderma, dermatomyositis, or vasculitis. The goal is to see if it's safe and can improve symptoms when other treatments haven't worked.
Taiyuan, ShanxiAges 18 years+ - NCT06084962RecruitingPhase 1
GPRC5D-targeted CAR-T cells for advanced multiple myeloma
This trial tests a new type of CAR-T cell therapy that targets a protein called GPRC5D on multiple myeloma cells. It is for people whose myeloma has not responded to or has returned after at least three prior treatments, and aims to see if this targeted approach can help control the disease.
Hangzhou, ZhejiangAges 18–75 - NCT06126406RecruitingPhase 1
CEA-targeting CAR-T cell therapy for advanced solid tumors
This trial tests a new immune cell therapy (CAR-T) designed to attack cancer cells that make a protein called CEA. It may be an option for people with advanced colorectal, esophageal, gastric, or pancreatic cancer who have already tried at least two standard treatments.
Wuhu, AnhuiAges 18 years+ - NCT06180174RecruitingPhase 1
CD19-targeted CAR-T cells for relapsed B-cell lymphoma
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06215950RecruitingPhase 1
CAR-T cell therapy for advanced gynecologic cancer with CD70 protein
This trial tests a new treatment called CAR-T cells that target a protein called CD70 found on some gynecologic cancer cells. It is for people whose cancer has advanced or spread and has not responded to or stopped responding to standard treatments.
Wuhu, AnhuiAges 18 years+ - NCT06279923RecruitingEarly Phase 1
CAR-T cells for autoimmune diseases
This trial tests a new CAR-T cell therapy that targets two immune proteins (CD19 and BAFF) to treat autoimmune diseases like lupus or scleroderma. It is for people who have not improved with standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06350110RecruitingPhase 1/Phase 2
CAR T cells for lupus
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
Beijing, Beijing MunicipalityAges 18–90 - NCT06633354RecruitingEarly Phase 1
CD5-targeted CAR T-cells for relapsed/refractory T-ALL
This trial tests a new type of immune therapy—called CD5-targeting CAR T-cells—for people with a hard-to-treat form of T-cell acute lymphoblastic leukemia. It aims to see if these specially designed cells can find and destroy leukemia cells with the CD5 marker.
Hangzhou, ZhejiangAges Any age - NCT06633341RecruitingEarly Phase 1
CAR-T cell therapy for CD5+ T-cell lymphoma
This trial tests a new treatment using your own immune cells, engineered to find and attack cancer cells that have a protein called CD5. It is for people with a type of T-cell lymphoma that has come back or not responded to other treatments.
Hangzhou, ZhejiangAges Any age - NCT06710717RecruitingPhase 1
CD19 CAR T-cells for severe lupus
This early-phase trial tests whether a patient's own immune cells (T-cells) that are modified to target a protein called CD19 can help people with severe lupus that hasn't improved with other treatments. The goal is to reduce lupus activity and possibly achieve remission.
Bandar Tun Razak, Kuala LumpurAges 18–65
Common questions
- Are there clinical trials studying CAR-T cells?
- Yes. Clin2 currently lists 534 recruiting studies that include CAR-T cells, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a CAR-T cells trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is CAR-T cells an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether CAR-T cells or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.